2018
DOI: 10.1091/mbc.e17-10-0577
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: This study analyzes the proteomes and phospho-proteomes of isogenic DLD-1 cancer cells differing in karyotypes and chromosome stability. Chromosome doubling is shown to trigger more extensive changes in (phospho-)proteomes than chromosome instability, and activation of mitotic pathways may explain differential responses to mitotic inhibitors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
30
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
2
2

Relationship

2
8

Authors

Journals

citations
Cited by 41 publications
(35 citation statements)
references
References 102 publications
5
30
0
Order By: Relevance
“…2). Similarly, recent analysis of aneuploid cancer cells has shown that these cells modulate their phospho-proteome and the microRNAome to adapt their physiology to the adverse effects of aneuploidy (65,66). Although evidence of proteome homeostasis as an aneuploidy maintenance mechanism has been gained from in vitro systems, studies in breast cancer supports the notion that attenuation of the effect of chromosome imbalances on protein levels also occurs in human tumors (67).…”
Section: Correcting the Consequences Of Cin: Dosage Compensation And mentioning
confidence: 99%
“…2). Similarly, recent analysis of aneuploid cancer cells has shown that these cells modulate their phospho-proteome and the microRNAome to adapt their physiology to the adverse effects of aneuploidy (65,66). Although evidence of proteome homeostasis as an aneuploidy maintenance mechanism has been gained from in vitro systems, studies in breast cancer supports the notion that attenuation of the effect of chromosome imbalances on protein levels also occurs in human tumors (67).…”
Section: Correcting the Consequences Of Cin: Dosage Compensation And mentioning
confidence: 99%
“…However, the identity of these gene(s) is at present unknown. Chromosome-specific and drug-specific interactions may complement the multi-drug resistance phenotype that has been observed in near-tetraploid cells that have undergone whole-genome duplications [40][41][42] . However, Mps1i treatment did not accelerate evolution in every context tested.…”
Section: Discussionmentioning
confidence: 99%
“…More specifically, (re)activation of the immune system can become a new therapeutic strategy to treat aneuploid tumours since aneuploid cells might be recognized by the innate immune system (table 1) [102]. Aneuploid cells with complex karyotypes trigger an upregulation of pro-inflammatory factors [32,102] and are cleared by natural killer cells in a co-culture setting [102].…”
Section: Activating the Immune System To Target Aneuploidymentioning
confidence: 99%